Cargando…
Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
Autor principal: | Dummer, Reinard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315226/ http://dx.doi.org/10.1186/1479-5876-13-S1-K18 |
Ejemplares similares
-
Evolution of resistance to MAPK-targeted therapies
por: Lo, Roger
Publicado: (2015) -
Combining radiation therapy with immunotherapy: clinical translation
por: Formenti, Silvia C
Publicado: (2015) -
Mechanisms of synergy of radiotherapy and immunotherapy
por: Pilones, Karsten A, et al.
Publicado: (2015) -
Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
por: Puzanov, Igor
Publicado: (2015) -
Surgery in the combination therapies era
por: Mozzillo, Nicola
Publicado: (2015)